Zvezdochka Flu powder d/d/internal 15g No. 10 orange
Compound
paracetamol 325 mg pheniramine maleate 20 mg phenylephrine hydrochloride 10 mg ascorbic acid 50 mg Excipients: povidone 25 mg, mannitol 2 g, calcium phosphate 30 mg, sucrose 11.29 g, citric acid 1 g, sodium citrate 100 mg, aspartame 10 mg, flavoring
Indications for use
- symptomatic treatment of “colds”, acute respiratory viral infections, incl. influenza (fever, pain, rhinorrhea).
Contraindications
- hypersensitivity; - children under 12 years of age; - phenylketonuria; - diabetes; - portal hypertension; - alcoholism; - renal failure; - pregnancy; - lactation period; - deficiency of glucose-6-phosphate dehydrogenase; - while taking tricyclic antidepressants, monoamine oxidase inhibitors (MAO), beta-blockers. With caution: Congenital hyperbilirubinemia (Gilbert, Dubin-Johnson and Rotor syndromes), children under 15 years of age, closed-angle glaucoma, prostatic hyperplasia, severe atherosclerosis of the coronary arteries, arterial hypertension, liver and/or kidney failure, pheochromocytoma.
Directions for use and doses
Inside. Dissolve the contents of one sachet in 1 glass of boiled hot water. Serve hot. You can add sugar to taste. A repeat dose can be taken every 4 hours (no more than 4 doses in 24 hours). Asterisk Flue can be used at any time of the day. If there is no relief of symptoms within 3 days after starting to take the drug, you should consult a doctor.
Storage conditions
In a dry place, protected from light, at a temperature of 15 to 25°C. Keep out of the reach of children.
Best before date
3 years
special instructions
During the treatment period, it is necessary to refrain from drinking ethanol (hepatotoxic effects may develop).
Description
granules from white to light orange in color with a slight odor of orange; the reconstituted solution is transparent or almost transparent light orange in color.
Conditions for dispensing from pharmacies
Over the counter
Dosage form
Powder for solution for oral administration
Use in children
Contraindicated for children under 12 years of age.
Manufacturer and organization accepting consumer complaints
DANAPHA PHARMACEUTICAL (Vietnam)
Action
Combined drug. Paracetamol is a non-narcotic analgesic, acting on the centers of pain and thermoregulation, and has an analgesic and antipyretic effect. Pheniramine is a blocker of H1-histamine receptors, reduces rhinorrhea and lacrimation, eliminates spastic phenomena. Phenylephrine is an adrenergic agonist with a moderate vasoconstrictor effect (stimulation of alpha1-adrenergic receptors). Ascorbic acid is involved in the regulation of redox processes, carbohydrate metabolism, blood clotting, tissue regeneration, and in the synthesis of steroid hormones; increases the body's resistance to infections, reduces vascular permeability; reduces the need for vitamins B1, B2, A, E, folic acid, pantothenic acid. Improves the tolerability of paracetamol and prolongs its effect (associated with prolongation of T1/2).
Side effects
Allergic reactions (skin rash, itching, urticaria, angioedema), nausea, epigastric pain; anemia, thrombocytopenia, agranulocytosis. Increased excitability, dizziness, increased blood pressure, difficulty falling asleep. Mydriasis, accommodation paresis, increased intraocular pressure, dry mouth; urinary retention. With long-term use in large doses - hepatotoxic effect, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia; nephrotoxicity (renal colic, glycosuria, interstitial nephritis, papillary necrosis).
Use during pregnancy and breastfeeding
Contraindicated during pregnancy and lactation.
Interaction
Enhances the effects of MAO inhibitors, sedatives, ethanol. Ethanol enhances the sedative effect of pheniramine, which is part of the drug. Pheniramine simultaneously with MAO inhibitors and furazolidone can lead to hypertensive crisis, agitation, and hyperpyrexia. Antidepressants, antiparkinsonian and antipsychotic drugs, phenothiazine derivatives increase the risk of developing urinary retention, dry mouth, and constipation. Glucocorticosteroids (GCS) increase the risk of developing increased intraocular pressure. Paracetamol reduces the effectiveness of uricosuric drugs and increases the effectiveness of indirect anticoagulants. Tricyclic antidepressants enhance their sympathomimetic effect; simultaneous administration of halothane increases the risk of developing ventricular arrhythmia. Reduces the hypotensive effect of guanethidine, which in turn enhances the alpha-adrenergic stimulating activity of phenylephrine.
Overdose
Symptoms (due to paracetamol): pale skin, decreased appetite, nausea, vomiting; hepatonecrosis (the severity of necrosis due to intoxication directly depends on the degree of overdose). Toxic effects in adults are possible after taking more than 10-15 g of paracetamol: increased activity of “liver” transaminases, increased prothrombin time (12-48 hours after administration); a detailed clinical picture of liver damage appears after 1-6 days. Rarely, liver failure develops rapidly and can be complicated by renal failure (tubular necrosis). Treatment: administration of SH-group donors and precursors for the synthesis of glutathione - methionine 8-9 hours after an overdose and N-acetylcysteine after 12 hours. The need for additional therapeutic measures (further administration of methionine, intravenous administration of N-acetylcysteine) is determined depending on on the concentration of paracetamol in the blood, as well as on the time elapsed after taking it.
Impact on the ability to drive vehicles and operate machinery
It is necessary to refrain from driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Zvezdochka Flu, 10 pcs., 15 g, powder for oral solution, raspberry
Paracetamol
Paracetamol enhances the effects of MAO inhibitors, sedatives, ethanol.
The risk of hepatotoxic action of paracetamol increases with simultaneous use of barbiturates (phenobarbital), phenytoin, carbamazepine, rifampicin, isoniazid, zidovudine and other inducers of microsomal liver enzymes.
With long-term regular use, paracetamol may enhance the anticoagulant effect of warfarin and other coumarin derivatives, and increase the risk of bleeding. A single dose of paracetamol does not have this effect.
When paracetamol is used simultaneously with metoclopramide, the rate of absorption of paracetamol increases and, accordingly, its maximum concentration in the blood plasma is reached faster. Likewise, domperidone may increase the rate of absorption of paracetamol. Concomitant use of chloramphenilol with paracetamol may increase the half-life of chloramphenilol.
Paracetamol may reduce the bioavailability of lamotrigine (by inducing hepatic metabolism) and reduce the effect of lamotrigine.
Absorption of paracetamol may be reduced when used concomitantly with cholestyramine. In this regard, it is recommended to take the drug Zvezdochka Flu 1 hour before taking cholestyramine. Regular use of paracetamol concomitantly with zidovudine may cause neutropenia and increase the risk of liver damage.
Probenecid affects the metabolism of paracetamol, and therefore the dose of paracetamol should be reduced in patients taking probenecid.
The hepatotoxicity of paracetamol may be increased by chronic or excessive alcohol consumption.
Paracetamol may interfere with laboratory determinations of uric acid using a precipitating agent.
Pheniramine
Pheniramine may enhance the effect of other drugs on the central nervous system (for example, MAO inhibitors, tricyclic antidepressants, alcohol, antiparkinsonian drugs, barbiturates, tranquilizers, narcotics). Ethanol enhances the sedative effect of pheniramine.
Pheniramine may inhibit the action of anticoagulants.
Phenylephrine
Zvezdochka Flu is contraindicated in patients who are concomitantly taking monoamine oxidase inhibitors (MAOIs) or have taken them within the previous two weeks, since phenylephrine can potentiate the effects of MAO inhibitors and cause a hypertensive crisis. Concomitant use of phenylephrine with other sympathomimetic drugs or tricyclic antidepressants (eg, amitriptyline) may increase the risk of adverse cardiovascular effects.
Phenylephrine may reduce the hypotensive effect of beta-blockers and other antihypertensive drugs (eg, guanethidine, reserpine, methyldopa). The risk of increased blood pressure and other cardiovascular side effects may be increased.
Concomitant use of phenylephrine with digoxin and other cardiac glycosides may increase the risk of arrhythmia or myocardial infarction
Concomitant use of phenylephrine with ergot alkaloids (ergotamine, methysergide) may increase the risk of developing ergotism.
